Neurocrine Biosciences
NBIX
$163.54
Share price
-1.49%
Change (1 day)
-14.69%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Total assets
Total assets on the balance sheet as of December 2024 : C$5.31 Billion
According to Neurocrine Biosciences 's latest financial reports the company's total assets are C$5.31 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Neurocrine Biosciences - Total assets on balance sheet (from 2001 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | C$5.33 B | 23.74% |
| 2023-12-31 | C$4.31 B | 34.17% |
| 2022-12-31 | C$3.21 B | 21.69% |
| 2021-12-31 | C$2.64 B | 19.41% |
| 2020-12-31 | C$2.21 B | 29.67% |
| 2019-12-31 | C$1.70 B | 26.08% |
| 2018-12-31 | C$1.35 B | 31.61% |
| 2017-12-31 | C$1.02 B | 109.51% |
| 2016-12-31 | C$0.49 B | -25.51% |
| 2015-12-31 | C$0.65 B | 133.52% |
| 2014-12-31 | C$0.28 B | 71.29% |
| 2013-12-31 | C$0.16 B | -15.51% |
| 2012-12-31 | C$0.19 B | 38.46% |
| 2011-12-31 | C$0.14 B | -2.51% |
| 2010-12-31 | C$0.14 B | 93.74% |
| 2009-12-31 | C$74.51 M | -48.14% |
| 2008-12-31 | C$0.14 B | -47.93% |
| 2007-12-31 | C$0.27 B | -39.17% |
| 2006-12-31 | C$0.45 B | -19.34% |
| 2005-12-31 | C$0.56 B | -9.81% |
| 2004-12-31 | C$0.62 B | -13.37% |
| 2003-12-31 | C$0.71 B | 71.01% |
| 2002-12-31 | C$0.42 B | -23.7% |
| 2001-12-31 | C$0.55 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 | C$4.04 B | -23.91% | 🇺🇸 USA |
 | C$26.03 B | 390.03% | 🇬🇧 UK |
 | C$6.15 M | -99.88% | 🇺🇸 USA |
 | C$112.47 B | 2,016.73% | 🇺🇸 USA |
 | C$193.13 B | 3,534.63% | 🇺🇸 USA |
 | C$304.93 B | 5,638.46% | 🇺🇸 USA |
 | C$1.83 B | -65.48% | 🇺🇸 USA |
 | C$10.61 M | -99.80% | 🇺🇸 USA |